Cystic Fibrosis: Diagnosis, Treatment, and Related Disorders

Guest Editors:

Dr. Miquéias Lopes-Pacheco
Biosystems & Integrative Sciences Institute (BioISI), Faculty of Sciences, University of Lisbon, 1749-016 Lisbon, Portugal

Dr. Neeraj Sharma
McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA

Dr. Shafagh Waters
School of Women's and Children's Health, Faculty of Medicine, University of New South Wales, Sydney, NSW 2052, Australia

Deadline for manuscript submissions:
closed (10 August 2023)

Message from the Guest Editors

Over the last decade, major clinical advances have been achieved in delaying cystic fibrosis (CF) progress with the implementation of newborn screening programs and development of novel therapies, including CFTR modulator drugs. Assessment of CFTR function and response to modulator drugs in CF carriers who present with CFTR-related disorders is warranted.

Many novel assays and models have emerged to better understand the genotype–phenotype relationship and to predict drug effectiveness in a personalized medicine approach. In parallel, mutation-agnostic therapies (i.e., independent of CFTR mutation) are under development.

This Special Issue on "Cystic Fibrosis" aims to gather a collection of reviews and original articles focused on "Diagnosis, Treatment, and Related Disorders" to this disease at basic, translational, and clinical levels to provide expert insights and perspectives on advances in the field.

Special Issue

Editor-in-Chief

Prof. Dr. David Alan Rizzieri
1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.
Journal Rank: JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us